Serologic evolution of neurocysticercosis patients after antiparasitic therapy

H. H. Garcia, R. H. Gilman, M. Catacora, M. Verastegui, A. E. Gonzalez, V. C.W. Tsang, M. Martinez, J. Altamirano, L. Trelles, J. M. Cuba, M. Alvarado, G. Alban, H. Estrada, N. Rios-Saavedra, M. Soto, M. P. Torres, J. Boero, C. Gavidia, E. Barron

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

78 Citas (Scopus)


Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.

Idioma originalInglés
Páginas (desde-hasta)486-489
Número de páginas4
PublicaciónJournal of Infectious Diseases
EstadoPublicada - 1997
Publicado de forma externa


Profundice en los temas de investigación de 'Serologic evolution of neurocysticercosis patients after antiparasitic therapy'. En conjunto forman una huella única.

Citar esto